ArticleFrontiers in allergy2026
A retrospective study on the effectiveness and safety of the combination of intranasal corticosteroid and intranasal antihistamine in the management of patients with allergic rhinitis.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Allergic Rhinitis and Its Impact on Asthma 2025 guideline recommends the combination of intranasal corticosteroid and intranasal antihistamine to be used as first-line treatment for moderate-to-severe allergic rhinitis because of its superior symptom control. This study was conducted to examine real-world evidence regarding the effectiveness and safety of the combination of Mometasone furoate and Azelastine (MF-Az) nasal sprays in Indian patients with allergic rhinitis. Methods: This multicentric, retrospective study was carried out across 424 ENT clinics in India. Medical records were scrutinized for information such as medical history, symptoms, clinical results, and adverse events (AEs). The mean change in total nasal symptom scores (TNSS) and total non-nasal symptom scores (TNNSS) from baseline to end of treatment was used to assess effectiveness. Independent EC approval was obtained before initiating the study. Results: The medical records of 4,500 patients with allergic rhinitis from 424 ENT clinics across India were screened. The mean change from baseline TNSS and TNNSS at Day 7 were -1.97 (±2.58) and -1.55 (±2.63), respectively, while those at Day 14 were -3.62 (±3.99) and -2.70 (±3.84), respectively. These changes were statistically significant ( Conclusion: The study concluded that intranasal MF-Az spray significantly alleviated nasal and non-nasal symptoms and was well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.